the long-term effects of new therapies on disease progression, including cancer risk, need to be investigated further [9]
The uricosuric agents targeting the URAT1 transporter, such as lesinurad and dotinurad, along with the formulation of oral combination therapies comprising xanthine oxidase inhibitors and uricosuric agents, is poised to improve the attainment of the target serum uric acid level of less than 6 mg/dL
The drug blocks the trans-membrane influx of calcium ions by inhibiting free voltage-dependent L-type calcium channels in vascular smooth muscles
NICE guidance recommends regular review of patients taking GLP-1 agonists, typically every 3-6 months, to assess treatment response, side effects, and ongoing appropriateness of therapy
stergaard SD, Hieronymus F
Medicine, 6(9), 102331